Terumo Establishes Corporate Venture Capital "Terumo Ventures"
TOKYO, Aug. 6, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for leading the Group's venture investments, as a department within Terumo Americas Holding, Inc. Terumo Vent...
FDA Clears the Individualized Nomogram for Rika Plasma Donation System
The latest innovation is anticipated to increase collection volume without increasing collection time * Rika's individualized nomogram, iNomi, can enable plasma donors to donate the right amount of plasma on any given day based on height, weight and hematocrit. * The Rika Plasma Donation Sys...
New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography
– Researchers used Terumo Health Outcomes' ePRISM® software to calculate safe
contrast volume targets and improve overall patient outcomes –
SOMERSET, N.J., Nov. 1, 2022 /PRNewswire/ -- A new study published in JAMA
Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan
Adjunctive use of Blood Glucose Meter Principally Not Required TOKYO, May 16, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announces that the indication for the Dexcom G6 CGM System has changed inJapan as ofMay 10, 2022. With this new indication, the Dexcom G6 CGM System will be the...
Terumo and Glooko Announce Collaboration on New Solution for Diabetes Data Sharing
A Technology Integration for MEDISAFE WITHTM Insulin Patch Pump Patients to
Upload Data Anytime Anywhere
TOKYO, March 30, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a
global leader in medical technology, andGlooko
Terumo Establishes Group-wide 'DE&I Philosophy' to Further Cultivate a Diverse, Equitable and Inclusive Culture
TOKYO, Mar. 1, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established a global "DE&I Philosophy" to further cultivate the culture of Diversity, Equity, and Inclusion (DE&I) at the Terumo Group. Additionally, a "DE&I Guiding Principle" has also been defined to ...
Terumo and Corazon Sign Collaboration and Co-Marketing Agreement
SOMERSET, N.J., Feb. 25, 2022 /PRNewswire/ -- Terumo Health Outcomes, a division of Terumo Medical Corporation, a leading global medical device manufacturer, has signed a collaboration and co-marketing agreement with Corazon, Inc., a leader in providing consulting, recruitment, interim managemen...
Terumo Medical Corporation Applauds ACC/AHA/SCAI Decision to Designate Radial Access Class 1, Level of Evidence A
SOMERSET, N.J., Jan. 11, 2022 /PRNewswire/ -- Terumo Medical Corporation (TMC) applauds the publication of updated guidelines from the American College of Cardiology (ACC), American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI) that give radial ac...
Terumo Corporation and Diabeloop SA. Enter into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care Offerings
TOKYO and PARIS, Nov. 17, 2021 /PRNewswire/ -- Terumo Corporation, a global leader in medical technology and the French company Diabeloop, a pioneer in therapeutic AI, announced today that they have signed an agreement for a comprehensive strategic partnership. With this agreement, in addition to...
Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcare
TOKYO, Sept. 17, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, today celebrates its 100th anniversary. The company, based inTokyo, boasts over 25,000 associates worldwide, providing products and services to more than 160 countries and regions across...
Terumo Blood and Cell Technologies and PhotonPharma Inc. announce collaboration to develop a novel cancer immunotherapy
1 in 3 people will be diagnosed with cancer in their lifetime1
LAKEWOOD, Colo. and FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Terumo
Blood and Cell Technologies
Terumo and UMCU strengthen their partnership to develop solutions in Interventional Oncology
LEUVEN, Belgium, July 20, 2021 /PRNewswire/ -- Terumo Europe and University Medical Center Utrecht (UMC Utrecht) announced today that they signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology. In the past years, both parties have successful...
Terumo Introduces New AZUR™ Vascular Plug and PG Pro™ Peripheral Microcatheter Embolization System
SOMERSET, N.J., July 14, 2021 /PRNewswire/ -- Terumo Medical Corporation (TMC) has announced today the introduction of its AZUR™ Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo's robust embolization po...
Terumo Donates Additional USD 1 Million to Support the COVID-19 Solidarity Response Fund for WHO
TOKYO, May 14, 2021 /PRNewswire/ -- As the world joins together to fight the ongoing battle against the COVID-19 pandemic, Terumo Corporation (TSE: 4543) has announced that the Terumo Group companies will collectively donateUSD 1 million in cash to support the COVID-19 Solidarity Response Fund fo...
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform
LAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device ...
Terumo is building a Global Therapeutic Interventional Oncology team to offer more therapeutic solution to cancer patients
LEUVEN, Belgium, April 12, 2021 /PRNewswire/ -- Terumo is proud to announce the launch of its Global Therapeutic Interventional Oncology team as ofApril 1st, 2021. This reflects Terumo's aspiration to be a Global leader in the field of Interventional Oncology by focusing on improving patient's qu...
Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.
TOKYO, Feb. 23, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS). HOS specializes in predictive analytics and clinical decision support that enable healthcare...
A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan
TOKYO, Feb. 8, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study inJapan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin). Kyowa Kirin initiated the clinica...
Terumo Enters 100th Anniversary Year
TOKYO, Jan. 5, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) is celebrating its 100th anniversary this year - marking 100 years of 'Contributing to Society through Healthcare' onSeptember 17, 2021. The company has established 'Stride Ahead' as a slogan, to celebrate and connect all Terumo ...
Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field
TOKYO and DEVENTER, Netherlands, July 15, 2020 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced it has completed the acquisition of Quirem Medical B.V., aNetherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radia...
